Samsung Biologics to Spin Off Biosimilar Unit, Launching a Two-Track Strategy
Samsung Group’s biopharmaceutical business is being reorganized into two separate tracks: CDMO (Contract Development and Manufacturing Organization) and…
Samsung Bioepis
8 개의 기사가 있습니다.
Samsung Bioepis Wins U.S. Injunction Case Over Stelara Biosimilar
Samsung Bioepis has cleared a key legal hurdle in the U.S. market for its autoimmune disease biosimilar Pyzchiva,…
Samsung Life Science Fund Invests $10 Million in U.S. Alzheimer’s Blood Test Company
Samsung Life Science Fund is investing $10 million in a company developing technology for Alzheimer’s disease diagnostics. Samsung…
Samsung Bioepis Appoints Kim Kyung-ah as New CEO After 13 Years
Samsung Bioepis announced a leadership change for the first time in 13 years. On the 27th, the company…
Samsung Bioepis Projected to Reach 1.4 Trillion KRW in Sales
Samsung Bioepis has surpassed its total annual revenue from last year within the first three quarters of 2023.…
Strong Performance Drives Samsung Biologics’ Price Target Upward
Following Samsung Biologics’ announcement of its third-quarter results, several securities firms have raised their target stock price for…
Samsung Bioepis Secures FDA Approval for High-Cost Rare Disease Drug in the U.S.
Samsung Bioepis announced on the 23rd that it has received approval from the U.S. Food and Drug Administration…
Samsung Bioepis’ Autoimmune Disease Treatment ‘PYZCHIVA’ Approved in the U.S.
Samsung Bioepis has announced that its biosimilar to Stelara, named ‘Pyzchiva’ (project name SB17, active ingredient ustekinumab), has…